TY - JOUR
T1 - Pituitary adenomas and oral contraceptives
T2 - A multicenter case-control study
AU - Gordis, L.
AU - Gold, E. B.
AU - Libauer, C.
N1 - Funding Information:
*Supported by the National Institute of Child Health and Human Development through contract numbers: HD-9-281O, HD-9-2811, HD-9-2812, and :aD-7-2834. Reprint requests: Ellen B. Gold, Ph.D., Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, 615 North Wolfe Street, Baltimore, Maryland 21205. Participants in the Pituitary Adenoma Study Group were Coordinating center: Leon Gordis, M.D., Dr.P.H., Ellen B. Gold, Ph.D., Charlotte Libauer, B.A., James A. Tonascia, Ph.D., and Susan Tonascia, Sc.M., The Johns Hopkins University, Baltimore, Maryland. Clinical centers: Robert B.
PY - 1983
Y1 - 1983
N2 - A case-control study was conducted to determine whether use of oral contraceptives (OCs) is associated with an increased risk of prolactin-secreting pituitary adenomas. Two hundred twelve women with such adenomas (140 of which were surgically confirmed) were recruited from four clinical centers and interviewed and matched by age and race to neighborhood control subjects. In addition, 119 hyperprolactinemic patients with amenorrhea and/or galactorrhea (A/G) who had normal or equivocal tomograms and 205 normoprolactinemic women with A/G were also interviewed and matched to neighborhood control subjects. No increase in relative odds (RO) for any of these groups of patients was found for use of OCs (pituitary adenoma cases versus controls RO = 1.33, 95% confidence intervals [CI = 0.81 to 2.22: equivocal cases versus controls RO = 1.35, 95% CI = 0.69 to 2.70; secondary A/G cases versus controls RO = 0.67, 95% CI = 0.37 to 1.18). History of infertility (RO = 25.5, 95% CI = 8.49 to 76.6), of menstrual problems or A/G (RO = 4.47, 95% CI = 2.21 to 9.05), and of nulliparity (RO = 4.36, 95% CI = 2.10 to 9.04) were each associated with a significantly increased risk of pituitary adenomas. The results of this study do not indicate any increase in risk of pituitary adenomas as a result of using OCs.
AB - A case-control study was conducted to determine whether use of oral contraceptives (OCs) is associated with an increased risk of prolactin-secreting pituitary adenomas. Two hundred twelve women with such adenomas (140 of which were surgically confirmed) were recruited from four clinical centers and interviewed and matched by age and race to neighborhood control subjects. In addition, 119 hyperprolactinemic patients with amenorrhea and/or galactorrhea (A/G) who had normal or equivocal tomograms and 205 normoprolactinemic women with A/G were also interviewed and matched to neighborhood control subjects. No increase in relative odds (RO) for any of these groups of patients was found for use of OCs (pituitary adenoma cases versus controls RO = 1.33, 95% confidence intervals [CI = 0.81 to 2.22: equivocal cases versus controls RO = 1.35, 95% CI = 0.69 to 2.70; secondary A/G cases versus controls RO = 0.67, 95% CI = 0.37 to 1.18). History of infertility (RO = 25.5, 95% CI = 8.49 to 76.6), of menstrual problems or A/G (RO = 4.47, 95% CI = 2.21 to 9.05), and of nulliparity (RO = 4.36, 95% CI = 2.10 to 9.04) were each associated with a significantly increased risk of pituitary adenomas. The results of this study do not indicate any increase in risk of pituitary adenomas as a result of using OCs.
UR - http://www.scopus.com/inward/record.url?scp=0020604056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020604056&partnerID=8YFLogxK
U2 - 10.1016/s0015-0282(16)47113-x
DO - 10.1016/s0015-0282(16)47113-x
M3 - Article
C2 - 6682810
AN - SCOPUS:0020604056
SN - 0309-1708
VL - 39
SP - 753
EP - 760
JO - Unknown Journal
JF - Unknown Journal
IS - 6
ER -